Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients-Reference-Cited by-同舟云学术

Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients

Published:2017-12 Issue:1 Volume:17 Page:
ISSN:1470-7330
Container-title:Cancer Imaging
language:en
Short-container-title:Cancer Imaging

Author:

Will Leon,Giesel Frederik L.,Freitag Martin T.,Berger Anne K.,Mier Walter,Kopka Klaus,Koerber Stefan A.,Rathke Hendrik,Kremer Christophe,Kratochwil Clemens,Kauczor Hans-Ulrich,Haberkorn Uwe,Weber Tim F.

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Radiological and Ultrasound Technology

Link

http://link.springer.com/content/pdf/10.1186/s40644-017-0132-6.pdf

Reference28 articles.

1. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3:524–48.

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

3. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517–23.

4. Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST. Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate-specific membrane antigen radioimmunotherapy. Adv Urol. 2012;2012:921674.

5. Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, Haberkorn U. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S–89S.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefit of including CT urography in [68Ga]PSMA-11 PET/CT with low-dose CT: first results from a larger prostate cancer cohort analysis;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2022-09

2. A 2022 International Survey on the Status of Prostate Cancer Theranostics;Journal of Nuclear Medicine;2022-08-11

3. The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT;Cancer Imaging;2020-09-22

4. Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy;Annals of Nuclear Medicine;2020-03-27

5. Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement;Journal of Nuclear Medicine;2019-09-27